Global Metabolomics Biomarker Market 2022-2028

Global Metabolomics Biomarker Market 2022-2028

Global metabolomics biomarkers market is estimated to grow at a CAGR of 12.8% during the forecast period. Metabolomics is referred to as the large-scale study of small molecules, commonly known as metabolites, within tissues, cells, biofluids, or organisms. Collectively, these small molecules and their interactions within a biological system are known as the metabolome. Metabolites have been used as biomarkers for decades. The oldest application of metabolomics involves identifying the presence of sugar in urine for diabetes. The study of metabolites results in a growing number of biomarkers that are transforming the healthcare and life science industry.

Metabolomics is a powerful tool as the metabolites and their concentrations reflect the primary biochemical activity and state of tissues/cells. The advancement of metabolomics technologies provides improved diagnosis, more appropriate therapeutic targets, and allows a more accurate prognosis of disease development. The recent development of instrumental systems such as mass spectrometry, ultra-performance liquid chromatography, high-resolution NMR spectroscopy, and more advanced bioinformatics and analytical technologies has facilitated more wide-ranging exposure of the metabolome.

Innovative development in informatics and analytical technologies and increasing pharmaceutical and biotech R&D expenditure is expected to significantly contribute to the market growth during the forecast period. Other factors such as ongoing research on metabolomics biomarkers and extensive application of metabolomics biomarkers such as in colorectal cancer detection are also expected to drive the market growth. Further, increasing pharmaceutical and biotech R&D expenditure is also contributing to the market.

However, some factors are restraining the market growth that includes limitations in biological and experimental measurements, the high capital cost of tools and instruments, and limited well-qualified researchers are hindering the growth of the market. The increasing demand for drug development and personalized medicine and huge investments in metabolomics biomarker market research is creating enormous opportunities for the market.

Segmental Outlook

The global metabolomics biomarker market is segmented on the basis of application, technology, and end-user. By application, the market is segmented into toxicological studies, drug testing, and diagnosis. Based on the technology, the market is segmented into chromatography, NMR, mass spectrometry, and others. By end-user, the market is segmented into hospitals and diagnostic labs & research centers.

The market is analyzed on the basis of application, technologies, and end-users segment. On the basis of application, the market is segmented into toxicological studies, drug testing, and diagnosis. The drug testing segment is projected to contribute a prominent share to the market. The market growth is attributed to the extensive use of metabolomics biomarkers for the discovery of novel methods or drugs to cure chronic diseases such as cancer, CVDs, neurological disorders, and many others. Moreover, many small and medium companies are emerging in the market to develop metabolomics biomarkers for the diagnosis of chronic diseases which fuels the segmental growth of the market.

Regional Outlooks

The global metabolomics biomarker market is analyzed on the basis of the geographical regions that are contributing significantly to the growth of the market. On the basis of geography, the market is divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America led the market and will maintain its dominance during the forecast. The regional growth of the market is attributed to the increasing funding support for biomarkers discovery and development and the growing usage of biomarkers in drug discovery & development within the region.

Market Players Outlook

Some of the key players of the metabolomics biomarker market include BG Medicine Inc., Biomark Diagnostics Inc., Evotec A.G., Merck KGaA, Metabolomic Diagnostics Ltd., Stemina Biomarker Discovery, Inc., and Thermo Fisher Scientific Inc., among others. The companies are developing innovative metabolomics biomarkers in the market, to develop effective diagnostic and treatment for infectious and metabolic diseases. Furthermore, to survive in the market, these players adopt different marketing strategies such as merger and acquisition, product launch, and geographical expansion. For instance, In November 2022, Metabolon, Inc. announced a new collaboration with Tracking Parkinson's, or the PRoBaND study, a UK-based longitudinal study of Parkinson's disease funded entirely by Parkinson's UK, to identify new metabolomic biomarkers and track biological changes over time to better understand Parkinson's disease pathogenesis. Further, in 2018 Agilent Technologies, Inc., established a partnership with BioTek Instruments, Inc. to launch a novel integrated solution combining cellular metabolic analysis and imaging technologies. This solution would integrate Agilent Seahorse XFe96/XFe24 Analyzers with the BioTekCytation 1 Cell Imaging Multi-Mode Reader. With this collaboration, the company is aimed at advancing scientific discovery through technological innovations.